MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-14-2026
Grifols, S.A. Shares 2011-2026 | GRFS
Annual Shares Grifols, S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 682 M | -24.9 B | -24.9 B | -77.7 B | -36.7 B | 127 M | -103 B | -108 B | -561 B | -370 B | -103 B |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 682 M | -561 B | -128 B |
Shares of other stocks in the Biotechnology industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
16.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M |  Canada |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
I-Mab
IMAB
|
187 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
17.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Cabaletta Bio
CABA
|
100 M | $ 2.82 | 1.44 % | $ 283 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | USA |
 |
Esperion Therapeutics
ESPR
|
208 M | $ 2.85 | 3.26 % | $ 592 M | USA |
 |
Acasti Pharma
ACST
|
12.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Equillium
EQ
|
57.3 M | $ 2.06 | - | $ 118 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
15.8 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
1.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
255 M | $ 1.29 | -3.01 % | $ 329 M | Britain |
 |
Stoke Therapeutics
STOK
|
59.2 M | $ 33.7 | -0.27 % | $ 2 B | USA |
 |
Atreca
BCEL
|
38.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.42 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
110 M | - | - | $ 546 M | USA |
 |
Heron Therapeutics
HRTX
|
167 M | $ 0.83 | 3.62 % | $ 138 M | USA |
 |
BioDelivery Sciences International
BDSI
|
99.3 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
54.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
69.9 K | - | - | $ 3.74 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
Avid Bioservices
CDMO
|
63.2 M | - | - | $ 789 M | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
Savara
SVRA
|
222 M | $ 5.25 | -0.57 % | $ 1.17 B | USA |
 |
China SXT Pharmaceuticals
SXTC
|
1.42 M | $ 1.32 | -5.2 % | $ 1.88 M | China |
 |
Bellerophon Therapeutics
BLPH
|
9.55 M | - | -74.18 % | $ 955 K | USA |
 |
Kala Pharmaceuticals
KALA
|
3.8 M | $ 0.2 | -6.67 % | $ 759 K | USA |
 |
Tarsus Pharmaceuticals
TARS
|
41.8 M | $ 67.2 | 0.36 % | $ 2.81 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
89.9 M | $ 47.55 | 0.98 % | $ 4.28 B |  Schweiz |
 |
Arbutus Biopharma Corporation
ABUS
|
192 M | $ 4.45 | -1.77 % | $ 853 M | Canada |
 |
AIkido Pharma
AIKI
|
6.18 M | - | 1.93 % | $ 17.4 M | USA |
 |
Allakos
ALLK
|
86.8 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
5.39 M | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
68 M | - | 3.16 % | $ 1.9 M | USA |